Core economic data released, CPI moderately rebounded, PPI decline narrowed. The credit structure continued to optimize in the first four months. Low end varieties+dividend varieties are relatively dominant. Industry Study: Pharmaceutical Outsourcing Industry (CXO). A new round of patent cliff is approaching, and innovative pharmaceutical companies urgently need new drugs to smooth their revenue curve. Faced with the uncertainty and high investment in new drug research and development, pharmaceutical companies are more willing to adopt the outsourcing CXO approach.
Core economic data released, CPI moderately rebounded, PPI decline narrowed. The credit structure continued to optimize in the first four months. Low end varieties+dividend varieties are relatively dominant. Industry Study: Pharmaceutical Outsourcing Industry (CXO). A new round of patent cliff is approaching, and innovative pharmaceutical companies urgently need new drugs to smooth their revenue curve. Faced with the uncertainty and high investment in new drug research and development, pharmaceutical companies are more willing to adopt the outsourcing CXO approach.